Home » Boehringer Releases Positive Results From Two Breast Cancer Trials of Afatinib
Boehringer Releases Positive Results From Two Breast Cancer Trials of Afatinib
Germany-based Boehringer Ingelheim has reported positive results from two trials (LUX-Breast 1 and LUX-Breast 3) evaluating afatinib to treat patients with breast cancer.
Pharmaceutical Business Review
Upcoming Events
-
07May
-
14May
-
30May